ArticleFrontiers in immunology2026
Histological grading of tertiary lymphoid structures correlates with renal impairment and adverse outcomes in ANCA-associated glomerulonephritis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tertiary lymphoid structures (TLS) are organized immune aggregates that develop in non-lymphoid tissues during chronic inflammation and are associated with adverse outcomes in various kidney diseases. Their role in antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis remains poorly characterized. Methods: This single-center retrospective study included 74 patients with biopsy-confirmed ANCA-associated glomerulonephritis. Intrarenal TLS were graded from G0 to G4 and dichotomized into low-grade (G0-2, n=37) and high-grade (G3-4, n=37). Clinical, laboratory, histopathological, and immunohistochemical parameters, systemic inflammatory indices, and progression to end-stage renal disease (ESRD) were compared between groups. Renal survival was analyzed using Kaplan-Meier and univariate and multivariate Cox regression to identify independent factors independently associated with ESRD. A prognostic nomogram incorporating these independently associated factors was constructed and internally validated using bootstrap-resampled calibration curves and the C-index. Results: High-grade TLS patients exhibited significantly lower estimated glomerular filtration rate (9.3 vs. 21.4 mL/min/1.73 m², p<0.001), higher Birmingham Vasculitis Activity Score (17.0 vs. 14.0, p=0.016), lower complement C3, and higher C-reactive protein, as well as a greater prevalence of crescentic/sclerotic histology (89.2% vs. 21.6%, p<0.001). High-grade TLS biopsies showed increased CD20+ B-cell and CD21+ follicular dendritic cell infiltration, while peripheral blood displayed a higher percentage of CD3+ T cells and an elevated Inflammation Burden Index (IBI). ESRD occurred in 51.4% of high-grade versus 27.0% of low-grade patients (p=0.032). High-grade TLS was associated with worse renal survival (log-rank p=0.021). In multivariate Cox regression, high-grade TLS, lower eGFR, lower complement C3, and sclerotic Berden class were identified as potential independent risk factors for ESRD in this cohort. A nomogram integrating these four predictors showed promising discriminative ability (C-index=0.897) and satisfactory calibration for predicting the probability of ESRD occurrence at 1 year. Conclusions: High-grade intrarenal TLS appear to be associated with more severe renal impairment, aggressive histopathology, and poor kidney survival in this ANCA-associated glomerulonephritis cohort. The finding that high-grade TLS may be independently associated with ESRD, together with the exploratory TLS-integrated nomogram, suggests a potential role for TLS grading in risk stratification. However, these preliminary findings warrant validation in larger prospective cohorts before any clinical application can be recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.